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Abstract
Dendrimer-based gene delivery has been constrained by intrinsic toxicity and suboptimal 
nanostructure. Conjugation of neutral morpholino oligonucleotides (ONs) with PAMAM 
dendrimers resulted in neutral, uniform, and ultra-small (~10nm) nanoconjugates. The 
nanoconjugates dramatically enhanced cellular delivery of the ONs in cancer cells. After release 
from the dendrimer in the cytosol, the ONs produced potent functional activity without causing 
significant cytotoxicity. When carrying an apoptosis-promoting ON, the nanoconjugates produced 
cancer cell killing directly. Thus, the dendritic nanoconjugates may provide an effective tool for 
delivering ONs to tumors and other diseased tissues.
Oligonucleotides (ONs) provide an opportunity for treating serious, life-threatening diseases 
that have limited therapeutic options using traditional small-molecule and antibody drugs. 
Antisense and siRNA ONs can modulate the expression of any gene and thus can target any 
protein by inducing enzyme-dependent degradation of target mRNAs.1 Further, steric-
blocking ONs, including splice switching ONs (SSOs), and antagomers of microRNA and 
long non-coding RNAs, block the access of cellular machinery to pre-mRNA or mRNA 
without causing enzymatic degradation of the RNA.2 For example, a morpholino antisense 
ON, capable of inducing exon skipping in dystrophin pre-mRNA, has shown to restore 
dystrophin function in patients with Duchenne muscular dystrophy in a phase II clinical 
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trial.3 Despite the enormous therapeutic potential, the development of ONs as therapeutic 
agents has been constrained by the inability of these hydrophilic and often charged 
macromolecules to reach their intracellular sites of action.4
Utilization of nanoparticles as delivery vehicle holds promise for unleashing the tremendous 
therapeutic potential of ONs. In this context, cationic dendrimers such as poly(amidoamine) 
(PAMAM) dendrimers have been widely used in ON delivery by condensing anionic ONs 
into nanoparticles.5 However, the use of dendrimers in biological systems is constrained by 
their inherent toxicity, which is attributed to the interaction of surface cationic residues of 
dendrimers with negatively charged biological membranes.5c Further, the method of 
complexation of cationic dendrimers with negatively charged ONs often leads to large 
(typically >100nm in diameter), heterogeneous and polydisperse structures, causing the 
problems such as limited biodistribution and low reproducibility. In this study, we use 
chemical conjugation methods to construct ultra-small neutral dendritic nanoconjugates that 
combine superior ON delivery and reduced cytotoxicity.
The overall strategy of this study is to link multiple neutrally charged ONs6 to a single 
molecule of PAMAM dendrimer via a reductively responsive linkage (Scheme 1).
The SSO623 (5′-GTTATTCTTTAGAATGGTGC-3′)7 and Mcl-1 SSO (5′-
CGAAGCATGCCTGAGAAAGAAAAGC-3′)8 were custom synthesized by Gene Tools, 
LLC (Philomath, OR). These ONs were phosphorodiamidate morpholino oligomers (PMOs) 
functionalized with a disulfide amide for sulfhydryl linkage at the 3′ position. PAMAM 
dendrimers G5 (Sigma-Aldrich) were reacted with a bifunctional crosslinker N-succinimidyl 
3-(2-pyridyldithio) propionate (SPDP, Thermo Fisher Scientific) at a 1:15 molar ratio of 
dendrimer to linker in PBS (pH7.5) for 1h at room temperature. The excess amount of SPDP 
was removed by gel filtration using a PD-10 Column (GE Healthcare). The average number 
of 2-pyridyldithio group (the sulfhydryl-reactive portion of SPDP) linked to dendrimer was 
determined as 12 by observing the release of pyridine-2-thione (λmax of 343nm) from the 
intermediate PAMAM-SPDP conjugates after being treated with an excess amount of DTT 
(Sigma-Aldrich). The thiol group on the PMO needed for conjugation with the 2-
pyridyldithio group on the dendrimer was freshly generated by treatment with 10mM DTT 
for 1h and any residual DTT was removed by gel filtration using a PD-10 Column. The 2-
pyridyldithio groups on the dendrimer were then reacted with the thiol group of PMO at a 
1:15 molar ratio of dendrimer to PMO in PBS with 1mM EDTA (pH7.0) overnight, and the 
final product was purified by gel filtration using a Sephadex G-100 gel column (GE 
Healthcare) to remove unreacted free PMOs. The number of PMOs linked to the dendrimer 
was estimated by measurement of pyridine-2-thione formation after the 3′-thiol PMO 
reacted with the SPDP-conjugated dendrimer as well as quantification of the PMO contents 
in the final product using OD260. These measurements led to close agreement with 9–11 
oligonucleotides linked per dendrimer in various preparations. The nanoconjugates were 
then termed PAMAM-PMO10. Preparation of fluorescent Dylight650-labelled 
nanoconjugates is described in the supporting information.
The final product of the nanoconjugates was analysed with size-exclusion chromatography 
using a Varian HPLC system (ProStar/Dynamax, Walnut Creek, CA) equipped with a Yarra 
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SEC-3000 column (Phenomenex, Torrance, CA). The PMO-containing samples were 
detected by OD260. As shown in Fig S1, the nanoconjugates eluted earlier than free PMOs 
in the column with the retention time of 8.2 and 10.1 min, respectively, indicating that the 
PMOs were successfully linked to the PAMAM dendrimers and the following purification 
step using the Sephadex G-100 gel column removed the remaining free PMOs from the 
nanoconjugates.
The average particle sizes and zeta potentials of the nanoconjugates were estimated using 
Zetasizer Nano (Malvern Instruments, Malvern, UK). We used polyplexes of the dendrimer 
with negatively charged ONs9 as a control. Average particle sizes for the starting material 
G5 PAMAM dendrimers, the nanoconjugates, and the polyplexes are summarized in Table 1 
and a representative size distribution graph is shown in Fig. 1A. The diameters for 
dendrimers, nanoconjugates, and polyplexes were 6.0, 9.6, and 500.9 nm, respectively. The 
nanoconjugates were visualized by transmission electron microscopy (LEO Electron 
Microscopy, Oberkochen, Germany), which revealed a uniform size distribution with a 
diameter averaging 10 nm (Fig. 1B).
Both PAMAM and the polyplexes showed strong positive zeta potential of over 10mV, 
while the PMO modified PAMAM showed low zeta potential of 1.9mV (Table 1), indicating 
that conjugation of neutral PMOs shielded the surface charge of PAMAM dendrimers. 
Similar charge shielding was observed when cationic nanoparticles were modified by neutral 
polymer polyethylene glycol (PEG).10 Since high positive charge is the main cause of 
cytotoxicity of PAMAM, conjugation with neutral ONs may decrease the toxicity of the 
dendrimer.
We then tested the serum stability of the disulfide linkage in the nanoconjugates by 
incubation in PBS with 20% serum at 37 °C for 16h. The incubated samples were eluted 
using a Sephadex G-100 gel, which separates the nanoconjugates from the PMOs. For the 
control and serum treated samples, the PMO contents (measured by OD260) eluted within 
the first 8 fractions (Fig. 2), indicating the PMOs were not cleaved by serum treatment and 
thus the nanoconjugates were stable in serum for at least 16h. Then, we tested whether 
intracellular sulfhydryls might release the PMOs from the nanoconjugates using PBS 
containing 10mM L-glutathione and 100μM cysteine, the typical free thiol concentrations in 
the cytosol.11 In gel filtration of the treated sample, over 84% of PMO contents eluted 
slower and overlapped the peak of free PMOs (Fig. 2), indicating that the majority of the 
PMOs were released from the nanoconjugates by the sulfhydryls. Thus, the ONs can be 
released from the nanoconjugates by cytosolic glutathione when delivered into the target 
cells.
Total cellular uptake of the nanoconjugates and free PMOs was evaluated by incubating 
A375 cells with these molecules for 4h and then measuring total cell-associated fluorescence 
by flow cytometry. As seen in Fig. 3A, there was a 273-fold greater uptake of the 
nanoconjugate as compared to free PMOs. In a previous study, antisense ONs were 
covalently conjugated to an anionic dendrimer and cellular uptake of the conjugates was 4-
fold greater than naked ON.12 Thus, the dendritic conjugates in this study may provide more 
potent cellular delivery of ONs. Pharmacological inhibitors were used to identify possible 
Ming et al. Page 3













endocytotic pathways. A375 cells were pre-treated with the inhibitors for 30 min and then 
treated with the nanoconjugates for 4h in the presence of the inhibitors followed by flow 
cytometry analysis. Four pharmacological inhibitors were used in the study to examine the 
possible endocytosis pathways: chlorpromazine (12.5μM), an inhibitor of the clathrin 
pathway; genistein, an inhibitor of caveolae pathway; amiloride (100μM), an inhibitor of 
macropinocytosis; and dynasore (30μM), a dynamin inhibitor.13 Treatment with dynasore 
abolished the uptake of the nanoconjugates, while genistein decreased the uptake in dose-
dependent manner (Fig. 3B). Thus, the nanoconjugates may undergo cell entry by the 
caveolae pathway.
To further understand the intracellular trafficking of the nanoconjugates after cellular entry, 
we utilized chimeras of GFP with marker proteins for specific endomembrane compartments 
to visualize the subcellular distribution of the targeted nanoconjugates in live cells. As seen 
in Fig. 4, there was considerable co-localization of the fluorescent nanoconjugates with 
Rab7 and Lamp1, markers for late endosome14 and lysosome15, respectively, indicating that 
the nanoconjugates were transported to late endosomes and lysosomes. This was confirmed 
by the substantial co-localization of the nanoconjugates with the lysosomal probe 
LysoTracker Green (Life technologies) (Fig. 4). In contrast, there was little co-localization 
of the nanoconjugate with Rab5, the early endosome marker (Fig. 4) and with the markers of 
mitochondria, Golgi network, and ER (Fig. S2). After trafficking to the late endosomes and 
lysosomes, the SSOs may undergo endosomal release and then transport to the nucleus to 
exert their pharmacological action.
Functional delivery by the nanoconjugates was tested in A375/eGFP654 cells that had been 
stably transfected with the eGFP gene interrupted by an abnormally spliced intron.16 
Successful delivery of SSO623, a model ON, to the cell nucleus leads to upregulation of 
eGFP expression, providing a positive read-out. A375/eGFP654 cells were treated with the 
nanoconjugates carrying SSO623 or with controls for 4h. After another 24h-culutre, eGFP 
induction in A375/eGFP654 cells was measured using flow cytometry. For comparison, we 
included the gold standard transfection reagent Lipofectamine 2000 and prepared its 
complexes with negatively charged phosphorothioate (PS) SSO623 as described 
previously.17 As indicated in Fig. 5A, treatment with the nanoconjugates produced a dose-
dependent increase in eGFP expression compared to little expression with free PMO. 
Compared to Lipofectamine 2000 complexes, the nanoconjugates demonstrated lower 
cytotoxicity and more uniform transfection (Fig. 5B). The dose of the SSO623 in the 
Lipofectamine 2000 complexes could only reach 200nM to avoid severe cytotoxicity. At this 
concentration, only 46% of A375/eGFP654 cells showed increased eGFP expression (Fig. 
5B). The nanoconjugates produced homogenous eGFP induction at all doses, and when the 
SSO concentration increased to 800nM, over 95% of the cells showed eGFP induction (Fig. 
5B) but no cytotoxicity was observed (Fig. S3). Thus, dendritic nanoconjugates may provide 
superior therapy in treating diseases that require uniform effects in all diseased cells, such as 
cancer.
The nanoconjugates achieve excellent delivery and low cytotoxicity. The nanoconjugates 
with neutral PMOs on the surface showed a moderate positive charge of 1.9mV, and thus 
cytotoxicity was likely reduced. As we designed a reductively responsive linkage between 
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the PMOs and PAMAM, the PMOs are probably released inside the endosomes of the cells. 
This may expose the strong positive charge of the dendrimers, causing endosomal 
membrane disruption and release of the PMOs.
To test therapeutic activity of the nanoconjugates, we prepared nanoconjugates carrying 
Mcl-1 SSO, which can redirect Mcl-1 splicing from anti-apoptotic Mcl-1L to pro-apoptotic 
Mcl-1S and thereby induce cancer cell apoptosis.8 By eliminating a cancer-permissive splice 
variant and inducing an apoptotic splice variant simultaneously, Mcl-1 SSO can potentially 
achieve greater cancer suppression than a Mcl-1L inhibitor that only acts on a single 
function. A375 cells were treated with nanoconjugates carrying Mcl-1 SSO (800nM) and 
other controls for 4h. Total RNA was isolated from the treated cells after 24-h culture and 
RT-PCR of Mcl-1 was performed using a method described in the Supporting Information. 
As shown Fig. 6A, treatment with the nanoconjugates carrying Mcl-1 SSO induced a 
substantial shift in Mcl-1 splicing from anti-apoptotic Mcl-1L to pro-apoptotic Mcl-1S, while 
treatment with the nanoconjugates carrying a mismatch SSO had no effect on splicing. We 
tested the cytotoxic activity of the nanoconjugates carrying Mcl-1 SSO. A375 cells were 
treated with the nanoconjugates for 4h. Cell viability was measured in the treated cells after 
72-h culture using the Alamar Blue assay. The nanoconjugates carrying Mcl-1 SSO caused 
death of 52% of A375 cells, which is comparable to that caused by Lipofectamine 
transfection of negatively charge Mcl-1 SSO (Fig. 6B). Again, treatment with the 
nanoconjugates carrying the mismatch SSO was not toxic to A375 cells, indicating that the 
toxicity was by functional delivery of Mcl-1 SSO by the nanoconjugates.
The results shown in Fig. 6 indicated therapeutic potential of neutral ON-dendrimer 
conjugates. Other SSOs that cause cancer cell killing include Bcl-x SSO18 and STAT3 
SSO19, and the nanoconjugates could also use them for cancer cell killing. Neutral ONs can 
be also used as antagomers of microRNA and long non-coding RNAs.2b Thus, this may 
provide a platform technology for using ONs in tumors and other diseased tissues.
Conclusions
Severe cytotoxicity is the main hurdle for in vivo application of dendrimers as drug carriers.5 
Interaction of dendrimers with biological membranes results in membrane disruption via 
nanohole formation, membrane thinning and erosion.5c Thus, PEGylation is the main 
approach to decrease the toxicity associated with dendrimers.5 Morpholino antisense 
oligonucleotides resemble PEG in many aspects including good water solubility, neutral 
charge, high stability, and nontoxicity.6 Further, the morpholino oligo itself is a therapeutic 
agent. Thus, conjugation of dendrimers with PMOs achieves dual purposes of enhancing 
cellular delivery and decreasing cytotoxicity. Even with reduced direct interaction of 
nanoconjugates with cell membranes, the dendritic nanoconjugates can still use the caveolae 
pathway to enter the cells. After reaching the endosomes in the cells, cytosolic glutathione 
cleaves disulphide bonds and releases PMOs from the dendrimers. The unconjugated 
dendrimers might disrupt the endosomal membrane to release the ONs to their sites of action 
in the nucleus, and thereby produce therapeutic actions.
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In conclusion, we have a utilized simple conjugation approach to construct neutrally charged 
and ultra-small nanoconjugates for ON delivery. The dendritic nanoconjugates showed 
excellent cellular uptake in cancer cells, and produced a dramatic increase in functional ON 
delivery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Characterization of Nanoconjugates. A. Overlay of DLC histograms of the nanoconjugates 
(red) and PAMAM polyplexes (green). B. TEM image of the nanoconjugates.
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Stability of disulfide linkage in serum and sulfhydryls. The nanoconjugates were incubated 
in serum-containing PBS for 16h or in PBS containing 10mM glutathione (GSH) and 
100μM cysteine for 4h, using PBS as a control. After incubation, samples were eluted using 
a Sephadex G-100 column. The ON content in the fractions was then detected by OD260.
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Intracellular uptake of nanoconjugates and effects of endocytosis inhibitors. Total cellular 
uptake of the Dylight650 labelled nanoconjugates and free PMOs (100nM) was evaluated by 
incubating cells with these molecules for 4h followed by flow cytometry. In an uptake 
inhibition experiment, the cells were pre-treated with the inhibitors and then treated with the 
nanoconjugates for 4 h in the presence of the inhibitors followed by flow cytometry analysis. 
***P < 0.001.
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Subcellular localization of the nanoconjugates. A375 cells were transfected with expression 
vectors for GFP chimeras that serve as markers for several endomembrane compartments 
(Rab5, early endosomes; Rab7, late endosomes; Lamp1, lysosome). Thereafter, cells were 
incubated with the fluorescent nanoconjugates (100nM) for 4h. Live cells were observed by 
confocal microscopy. In co-localization with LysoTracker, the cells were treated with 
LysoTracker and the nanoconjugates for 4h followed by imaging.
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Functional delivery of SSOs by the nanoconjugates. A. Comparison of dose-dependent 
eGFP induction by treatments with PMO and PAMAM-PMO10. B. Comparison of eGFP 
induction by the treatments of PAMAM-PMO10 and Lipoplexes of PS SSO.
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Functional delivery of Mcl-1 SSO using nanoconjugates. (a) RT-PCR of total RNA from 
A375 cells after treatments. (b) In vitro cytotoxicity caused by functional delivery of Mcl-1 
SSO. *** p < 0.001.
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Preparation of dendritic nanoconjugates.
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Table 1
Particle sizes, polydispersity index (P.I.) and zeta potentials of the nanoconjugates and polyplexes. Results are 
expressed as mean ± SD (n = 3 or 5)
Particle Size (nm) P.I. Zeta Potential (mV)
PAMAM 6.0 ± 0.1 0.36 ± 0.04 16.2 ± 0.7
Nanoconjugates 9.6 ± 0.2 0.41 ± 0.03 1.9 ± 0.5
Polyplexes 500.9 ± 60.2 0.164 ± 0.12 10.1 ± 0.4
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